Anand Rathi: Healthcare Q2 Review - Margin Elevation Drives Growth; Benefits To Moderate In H2
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Anand Rathi Report
Q2 FY21 sales of the companies we cover grew 11.2% to Rs 161 billion, driven by supply of Covid-19-related drugs, a surge in demand for active pharmaceutical ingredients and relatively stable pricing in the U.S.
Supported by less promotional spending, the Ebitda margins of most companies with a sizeable India business expanded.
Those of the companies we cover expanded 479 basis points to 27.6% (down 113 basis points sequentially). Their adjusted profit after tax grew 40.3% to Rs 30.2 billion.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the brokerage and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.